Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of...
-
OTTAWA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The Royal Society of Canada (RSC) has formed an Expert Panel to prepare a Policy Briefing on the applications, limitations and potential of wastewater...
-
Toronto, ON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Parents everywhere are trying to find the best ways to incorporate or limit technology in their children’s lives—and the pandemic hasn’t made it any...
-
OTTAWA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- The Ericsson-Carleton University Partnership for Research and Leadership in 5G Wireless Networks has established a new $2-million Ericsson Chair in 5G...
-
HOUSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Carriage Services, Inc. (NYSE: CSV) today announced results for the fourth quarter and year ended December 31, 2021. Full Year...
-
LAS VEGAS, Feb. 18, 2022 (GLOBE NEWSWIRE) -- The Fantasy Sports & Gaming Association (FSGA) announced the winners of its 2021 Industry Awards at the annual FSGA Winter Conference in Las Vegas. ...
-
EDMONTON, Alberta, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Im Vorfeld der AI Week, die vom 24. bis 27. Mai 2022 stattfindet, hat das Alberta Machine Intelligence Institute (Amii) die ersten...
-
EDMONTON, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- In anticipation of AI Week, May 24 - 27, 2022, the Alberta Machine Intelligence Institute (Amii) announced the first $100,000 in travel bursaries...
-
VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mining for Miracles, the BC mining industry’s long-standing fundraising campaign for BC Children’s Hospital Foundation, launched its...
-
PARAMUS, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced...